Actinium Pharmaceuticals Stock Performance

ATNM Stock  USD 1.23  0.03  2.50%   
Actinium Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.29, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Actinium Pharmaceuticals will likely underperform. Actinium Pharmaceuticals right now shows a risk of 5.04%. Please confirm Actinium Pharmaceuticals treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Actinium Pharmaceuticals will be following its price patterns.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Actinium Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Actinium Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Last Split Factor
1:30
Dividend Date
2020-08-11
Last Split Date
2020-08-11
1
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
01/13/2025
2
Acquisition by Seth Sandesh of 8125 shares of Actinium Pharmaceuticals at 0.6 subject to Rule 16b-3
02/28/2025
3
Leading Radiotherapy Company Actinium Opens Exclusive Investor Access at ROTH 2025 - StockTitan
03/12/2025
4
What Factors Are Driving Market Activity for Actinium Pharmaceuticals
03/13/2025
Begin Period Cash Flow109.6 M
  

Actinium Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  122.00  in Actinium Pharmaceuticals on December 17, 2024 and sell it today you would earn a total of  1.00  from holding Actinium Pharmaceuticals or generate 0.82% return on investment over 90 days. Actinium Pharmaceuticals is currently generating 0.134% in daily expected returns and assumes 5.0359% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Actinium, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Actinium Pharmaceuticals is expected to generate 5.59 times more return on investment than the market. However, the company is 5.59 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.08 per unit of risk.

Actinium Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Actinium Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Actinium Pharmaceuticals, and traders can use it to determine the average amount a Actinium Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0266

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskATNMHuge Risk
Negative Returns

Estimated Market Risk

 5.04
  actual daily
44
56% of assets are more volatile

Expected Return

 0.13
  actual daily
2
98% of assets have higher returns

Risk-Adjusted Return

 0.03
  actual daily
2
98% of assets perform better
Based on monthly moving average Actinium Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Actinium Pharmaceuticals by adding it to a well-diversified portfolio.

Actinium Pharmaceuticals Fundamentals Growth

Actinium Stock prices reflect investors' perceptions of the future prospects and financial health of Actinium Pharmaceuticals, and Actinium Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Actinium Stock performance.

About Actinium Pharmaceuticals Performance

By examining Actinium Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Actinium Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Actinium Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.54)(0.51)
Return On Capital Employed(0.82)(0.78)
Return On Assets(0.54)(0.51)
Return On Equity(1.54)(1.47)

Things to note about Actinium Pharmaceuticals performance evaluation

Checking the ongoing alerts about Actinium Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Actinium Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Actinium Pharmaceuticals had very high historical volatility over the last 90 days
Actinium Pharmaceuticals may become a speculative penny stock
The company reported the previous year's revenue of 81 K. Net Loss for the year was (48.82 M) with profit before overhead, payroll, taxes, and interest of 81 K.
Actinium Pharmaceuticals currently holds about 116.33 M in cash with (47.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from kalkinemedia.com: What Factors Are Driving Market Activity for Actinium Pharmaceuticals
Evaluating Actinium Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Actinium Pharmaceuticals' stock performance include:
  • Analyzing Actinium Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Actinium Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Actinium Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Actinium Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Actinium Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Actinium Pharmaceuticals' stock. These opinions can provide insight into Actinium Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Actinium Pharmaceuticals' stock performance is not an exact science, and many factors can impact Actinium Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.39)
Revenue Per Share
0.003
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.33)
Return On Equity
(1.00)
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.